Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
348
mi
from 43215
Charlotte, NC
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
348
mi
from 43215
Charlotte, NC
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
344
mi
from 43215
Richmond, VA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
344
mi
from 43215
Richmond, VA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
330
mi
from 43215
Milwaukee, WI
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
330
mi
from 43215
Milwaukee, WI
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
622
mi
from 43215
Little Rock, AR
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
622
mi
from 43215
Little Rock, AR
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
186
mi
from 43215
Jeffersonville, IN
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
186
mi
from 43215
Jeffersonville, IN
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
324
mi
from 43215
Chevy Chase, MD
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
324
mi
from 43215
Chevy Chase, MD
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
515
mi
from 43215
Albany, NY
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
515
mi
from 43215
Albany, NY
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
78
mi
from 43215
Lima, OH
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
78
mi
from 43215
Lima, OH
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
1667
mi
from 43215
Peoria, AZ
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1667
mi
from 43215
Peoria, AZ
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
643
mi
from 43215
Boston, MA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
643
mi
from 43215
Boston, MA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
394
mi
from 43215
St Louis, MO
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
394
mi
from 43215
St Louis, MO
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
515
mi
from 43215
Albany, NY
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
515
mi
from 43215
Albany, NY
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
2006
mi
from 43215
Mountlake Terrace, WA
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2006
mi
from 43215
Mountlake Terrace, WA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
551
mi
from 43215
Newington, CT
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
551
mi
from 43215
Newington, CT
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
643
mi
from 43215
Boston, MA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
643
mi
from 43215
Boston, MA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
515
mi
from 43215
Albany, NY
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
515
mi
from 43215
Albany, NY
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
78
mi
from 43215
Lima, OH
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
78
mi
from 43215
Lima, OH
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
1514
mi
from 43215
Ogden, UT
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1514
mi
from 43215
Ogden, UT
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Clinical Trial Facility
330
mi
from 43215
Milwaukee, WI
A Safety and Efficacy Study of 26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
330
mi
from 43215
Milwaukee, WI
Duloxetine for Menopausal Depression
Duloxetine for Menopausal Depression
Status: Archived
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Duloxetine for Menopausal Depression
Duloxetine for Menopausal Depression
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Mothers With a History of Depression and Their 10-14 Year Old Daughters
The Neural Correlates of Mood and Cognitive Bias in a Population at Risk for Depression: Maternal Cognitive and Emotional Functioning
Status: Archived
Stanford Clinical Research Center
2100
mi
from 43215
Stanford, CA
Mothers With a History of Depression and Their 10-14 Year Old Daughters
The Neural Correlates of Mood and Cognitive Bias in a Population at Risk for Depression: Maternal Cognitive and Emotional Functioning
Status: Archived
Updated: 1/1/1970
Stanford Clinical Research Center
2100
mi
from 43215
Stanford, CA
Mothers With a History of Depression and Their 10-14 Year Old Daughters
The Neural Correlates of Mood and Cognitive Bias in a Population at Risk for Depression: Maternal Cognitive and Emotional Functioning
Status: Archived
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Mothers With a History of Depression and Their 10-14 Year Old Daughters
The Neural Correlates of Mood and Cognitive Bias in a Population at Risk for Depression: Maternal Cognitive and Emotional Functioning
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
PET Whole Body Distribution Studies Using [11C]CUMI
PET Whole Body Distribution Studies Using the 5-HT1A Agonist, [11C]CUMI
Status: Archived
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
PET Whole Body Distribution Studies Using [11C]CUMI
PET Whole Body Distribution Studies Using the 5-HT1A Agonist, [11C]CUMI
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Activating Messages for Enhancing Primary Care Practice (AMEP2): Effectiveness Study
Targeted and Tailored Messages to Enhance Depression Care
Status: Archived
Uc Irvine Medical Center
1959
mi
from 43215
Orange, CA
Activating Messages for Enhancing Primary Care Practice (AMEP2): Effectiveness Study
Targeted and Tailored Messages to Enhance Depression Care
Status: Archived
Updated: 1/1/1970
Uc Irvine Medical Center
1959
mi
from 43215
Orange, CA
Activating Messages for Enhancing Primary Care Practice (AMEP2): Effectiveness Study
Targeted and Tailored Messages to Enhance Depression Care
Status: Archived
Unversity of California, San Francisco
2108
mi
from 43215
San Francisco, CA
Activating Messages for Enhancing Primary Care Practice (AMEP2): Effectiveness Study
Targeted and Tailored Messages to Enhance Depression Care
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
2108
mi
from 43215
San Francisco, CA
The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse
The Effects and Mechanisms of MBCT on Depressive Symptoms and Depression Relapse
Status: Archived
University of Denver
1131
mi
from 43215
Denver, CO
The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse
The Effects and Mechanisms of MBCT on Depressive Symptoms and Depression Relapse
Status: Archived
Updated: 1/1/1970
University of Denver
1131
mi
from 43215
Denver, CO
Computerized Information-Processing Bias Retraining in Depressed Adolescents
Computerized Information-Processing Bias Retraining in Adolescents With Depression: A Controlled Trial
Status: Archived
Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital
641
mi
from 43215
Cambridge, MA
Computerized Information-Processing Bias Retraining in Depressed Adolescents
Computerized Information-Processing Bias Retraining in Adolescents With Depression: A Controlled Trial
Status: Archived
Updated: 1/1/1970
Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital
641
mi
from 43215
Cambridge, MA
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
551
mi
from 43215
Newington, CT
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
551
mi
from 43215
Newington, CT
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
Safety and Efficacy of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
341
mi
from 43215
Centralia, IL